Navigation Links
FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab
Date:2/18/2009

hey are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.

    CONTACT: Amgen, Thousand Oaks
    Sarah Reines: (805) 447-9783 (media, osteoporosis)
    Lisa Rooney: (805) 447-6437 (media, oncology)
    Arvi
'/>"/>
SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. FDA Accepts Cell Therapeutics Zevalin sBLA and Grants Priority Review
2. NYSE Alternext US Accepts China Shenghuos Compliance Plan for Continued Listing
3. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
4. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
5. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
6. FDA Accepts Immucors Response to Warning Letter
7. FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
8. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
9. Imaging Diagnostic Systems Accepts Resignations of Outside Directors
10. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
11. FDA Accepts Ranexa(R) sNDA and NDA for Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... throughput research solutions, today announced that Lupin Limited, one ... of Freeslate’s CM Protégé PharmD System for ... in Mumbai, India, is focused on a wide range ...
(Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... based on the products of cells grown under simulated ... an international license agreement with Suneva Medical, Inc. for ... media (CCM). , This agreement is an ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... Ontario , Jan. 14, 2014   Kinaxis ®, provider ... SCM ) and sales and operations planning ( S&OP ) ... Biomanufacturing Summit , which will be held at the ... the conference, join Kinaxis customer Elisabeth Kaszas , Director ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... YORK, June 8, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0548785/Future-of-White-Biotechnology-in-China.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory ... referred to the third wave in biotechnology, ...
... 7, 2011 Vaxart, Inc., a San Francisco biotechnology company ... I clinical trial. This is the first clinical study evaluating ... The trial site is in the United States. ... is demonstrated with one vaccine, we can expect that later ...
... 7, 2011 Infrared Systems International (OTCBB: IFRS) is pleased ... pilot study of its NatuRx™ HIV/AIDS treatment and will push ... AquaLiv concluded a pilot study with two HIV/AIDS patients ... of the first reported AIDS victims on June 5th, 1981. ...
Cached Biology Technology:Reportlinker Adds Future of White Biotechnology in China 2Reportlinker Adds Future of White Biotechnology in China 3Reportlinker Adds Future of White Biotechnology in China 4Reportlinker Adds Future of White Biotechnology in China 5Vaxart Begins First Oral Vaccine Clinical Trial 2Infrared Systems International's Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS 2Infrared Systems International's Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS 3
(Date:4/22/2014)... research projects study the effects of temperature and precipitation ... However, an important component of climate research, the UV-B ... in collaboration with their colleagues from the Universities in ... from the U.S. NASA space agency in such a ... influence of UV-B radiation on organisms. , The basic ...
(Date:4/22/2014)... another way of asking him or her to behave ... cells of the immune system tend to misbehave with ... these cells are known to misbehave similarly during spaceflight, ... cells to better understand how our immune systems change ... on Aging, part of the National Institutes of Health, ...
(Date:4/22/2014)... Recent projects in two Minnesota cities demonstrate how ... projects continue a ten year program in New ... plans tailored to local conditions. , "Our goal ... protect themselves," said program co-leader Latham Stack, of ... have already worsened. We help communities move beyond ...
Breaking Biology News(10 mins):UV-radiation data to help ecological research 2For an immune cell, microgravity mimics aging 2For an immune cell, microgravity mimics aging 3For an immune cell, microgravity mimics aging 4For an immune cell, microgravity mimics aging 5Minnesota projects offer hope and practical help to communities facing more extreme storms 2
... the journal Clinical Cancer Research, a journal ... non-invasive screening method with future potential for detection of ... In the study, researchers at Johns Hopkins University used ... identify oral HPV infections in patients with HPV16-positive and ...
... one in the United States and one in Australia, ... visualizing the invisible processes at work in several human ... the Optical Society,s (OSA) Interactive Science Publishing (ISP) initiative, ... large three-dimensional data and gives researchers, scientists and engineers ...
... 29, 2008 -- Vitamin E has been heralded for its ... and sudden death. Yet in some people, vitamin E causes ... excess vitamin E promotes bleeding by interfering with vitamin K, ... able to pinpoint how the two vitamins interact. Nutrition researcher ...
Cached Biology News:Oral rinses used for tracking HPV-positive head and neck cancers holds promise for cancer screening 2OSA's ISP launches with research on breathing disorders and congenital heart defects 2OSA's ISP launches with research on breathing disorders and congenital heart defects 3OSA's ISP launches with research on breathing disorders and congenital heart defects 4
These 25x25 square No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 102...
... of Cell Cultures (ECACC) has been offering ... and government institutes for over seven years. ... to introduce candidates to cell culture and ... more specialist areas such as planning and ...
...
These 22x40mm rectangular No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 73...
Biology Products: